Licarbazepine

Licarbazepine
	Top: (R)-(−)-licarbazepine; Bottom: (S)-(+)-licarbazepine
Clinical data
ATC code	None;
Pharmacokinetic data
Protein binding	<40%
Metabolites	Glucuronides
Excretion	Mainly renal
Identifiers
	IUPAC name (RS)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide;
CAS Number	29331-92-8;
PubChem CID	114709;
ChemSpider	102704;
UNII	XFX1A5KJ3V;
KEGG	D09215;
ChEMBL	ChEMBL1067;
CompTox Dashboard (EPA)	DTXSID50865484 ;
ECHA InfoCard	100.122.427
Chemical and physical data
Formula	C15H14N2O2
Molar mass	254.289 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES NC(=O)N1c2ccccc2CC(O)c3ccccc13;
	InChI InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19); Key:BMPDWHIDQYTSHX-UHFFFAOYSA-N;

Licarbazepine is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects that is related to oxcarbazepine.^[1] It is an active metabolite of oxcarbazepine.^[1]^[2] In addition, an enantiomer of licarbazepine, eslicarbazepine ((S)-(+)-licarbazepine), is an active metabolite of eslicarbazepine acetate.^[1]^[2] Oxcarbazepine and eslicarbazepine acetate are inactive on their own, and behave instead as prodrugs to licarbazepine and eslicarbazepine, respectively, to produce their therapeutic effects.^[1]^[2]